Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 31

Strong Balance Sheet Key Metrics (unaudited) 12/31/18 balance Total Cash, Cash Equivalents, and Marketable Securities $293.2 million Long-term Debt Obligation $229.0 million Basic Shares Outstanding 32,284,602 Total Potentially Dilutive Securities*  16,709,048 Funding Projected through Q1 2021 * Includes common stock issuable under the April 2018 convertible debt offering, options, restricted share units , warrants, and shares available for purchase under our ESPP